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Abstract
Nipah virus (NiV) is an enigmatic emerging pathogen that causes severe and often fatal neurologic and/or respiratory
disease in both animals and humans. Amongst people, case fatality rates range between 40 and 75 percent and there are no
vaccines or treatments approved for human use. Guinea pigs, hamsters, cats, ferrets, pigs and most recently squirrel
monkeys (New World monkey) have been evaluated as animal models of human NiV infection, and with the exception of
the ferret, no model recapitulates all aspects of NiV-mediated disease seen in humans. To identify a more viable nonhuman
primate (NHP) model, we examined the pathogenesis of NiV in African green monkeys (AGM). Exposure of eight monkeys to
NiV produced a severe systemic infection in all eight animals with seven of the animals succumbing to infection. Viral RNA
was detected in the plasma of challenged animals and occurred in two of three subjects as a peak between days 7 and 21,
providing the first clear demonstration of plasma-associated viremia in NiV experimentally infected animals and suggested a
progressive infection that seeded multiple organs simultaneously from the initial site of virus replication. Unlike the cat,
hamster and squirrel monkey models of NiV infection, severe respiratory pathology, neurological disease and generalized
vasculitis all manifested in NiV-infected AGMs, providing an accurate reflection of what is observed in NiV-infected humans.
Our findings demonstrate the first consistent and highly pathogenic NHP model of NiV infection, providing a new and
critical platform in the evaluation and licensure of either passive and active immunization or therapeutic strategies for
human use.
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Introduction
Nipah virus (NiV) is a recently recognized viral zoonotic
pathogen of the family Paramyxoviridae that is distinguished by its
ability to cause fatal disease in both animal and human hosts. NiV
along with Hendra virus (HeV) comprise the new genus Henipavirus
(reviewed [1,2]). NiV was first identified during an outbreak of
severe encephalitis in Malaysia and Singapore in 1998–99 that
involved hundreds of people and more than 100 deaths, with pigs
serving as the intermediate amplifying host [3,4]. Since 1998 there
have been more than a dozen recognized occurrences of human
NiV infection, primarily in Bangladesh and India (reviewed [5])
with the two most recent outbreaks in March 2008 [6] and January
2010 [7]. In the majority of subsequent spillover events, the
mortality rate among humans has been higher (,75%) along with
evidence of multiple rounds of person-to-person transmission [8].
Several species of fruit bats of the Pteropus genus (flying foxes)
appear to be the principle natural reservoirs of both NiV and HeV
(reviewed [5]) but serological evidence of NiV or Nipah-like virus
infection has recently been reported in several additional
frugivorous and insectivorous bats [9,10]. NiV has been isolated
from bat urine and partially eaten fruit [11,12] and direct
transmission of NiV from flying foxes to humans from contam-
inated food sources has been suggested [13,14]. The Centers for
Disease Control and Prevention (CDC) and the National Institute
of Allergy and Infectious Diseases (NIAID) have classified NiV as a
select agent with the potential for causing significant morbidity
and mortality in humans and major economic and public health
impacts. Consequently, work with live virus requires Biosafety
Level 4 (BSL-4) containment.
Host cell infection by NiV requires two membrane-anchored
envelope glycoproteins; the attachment glycoprotein (G) which
binds receptor and the fusion (F) glycoprotein which facilitates
virus-host cell membrane fusion [2]. NiV G lacks hemagglutinin
and neuraminidase activities and F is a typical class I fusion
glycoprotein [15]. Recently, ephrin-B2 and ephrin-B3 ligands
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were identified as receptors employed by the henipaviruses for
infection [16,17,18,19]. For paramyxoviruses, the majority of
virus-neutralizing antibody is directed towards these two envelope
glycoproteins with the attachment glycoprotein serving as the
dominant target antigen [20,21,22]. Indeed, recombinant soluble
G from HeV and NiV has been successfully employed as a subunit
vaccine in a NiV challenge model in the cat [23,24], and evidence
of passive antibody protection against NiV and HeV challenge in
the hamster has been reported [25,26,27]. More recently a cross
reactive, neutralizing and fully human monoclonal antibody has
been shown to be an effective post-exposure therapeutic against
NiV in a new ferret model [28]. However, there are currently no
vaccines or therapeutic modalities approved for the prevention or
treatment of henipavirus infections in humans.
The development and characterization of suitable animal
models for henipavirus infection is essential for understanding
their pathogenic characteristics and mechanisms as well as
fulfilling the critical needs for the in vivo evaluation of potential
antiviral modalities for human use. To date, guinea pigs, golden
hamsters, cats, ferrets and pigs have been evaluated as exper-
imental animal models of human NiV infection (re-
viewed[5,29,30]). The restriction of live henipavirus experimenta-
tion to BSL-4 containment has significantly hampered the
development of henipavirus countermeasures in a rapid and
systematic fashion. In addition, the U.S. Food and Drug
Administration (FDA) has implemented the Animal Efficacy Rule
which came into effect in 2002. This rule specifically applies to the
development of therapeutic products when human efficacy studies
are not possible or ethical, such as is often the case with highly
virulent emerging pathogens like NiV. Essentially, this rule allows
for the evaluation of vaccines or therapeutics using data derived
from studies carried out in at least two animal models. Although
the ferret seems to be the most accurate animal model developed
thus far, the licensure of any antiviral therapeutic for NiV will
likely also require an evaluation of NiV pathogenesis in nonhuman
primates. However, there has been little experimentation directed
towards the evaluation of henipavirus infection outcomes in
nonhuman primates. Here we describe a new animal model of
acute NiV infection and associated disease in the African green
monkey (AGM).
Results
Nipah Virus Infection and Pathogenesis in African Green
Monkeys
There is no information presently available on the sequence
homology between the human and African green monkey (AGM)
(Chlorocebus aethiops) ephrin-B2 or ephrin-B3 receptors. However,
we reasoned that the human and AGM ephrins should be quite
similar given the high amino acid sequence homology across a
variety of vertebrate species. While none of the henipaviruses have
been specifically adapted to a simian host or for usage of a simian
ephrin receptor protein NiV and HeV replicate to very high titers
(.107) in Vero cells which are derived from AGMs. We first
performed a challenge study in three AGMs (Subjects 1–3) with
doses ranging from 7.06103 to 1.36106 plaque forming units (pfu)
of NiV by intratracheal (i.t.) and oral delivery. In this initial
experiment, the monkeys appeared highly susceptible to acute
disease caused by exposure to NiV (Table 1). All three animals
became severely ill with symptoms highly consistent with human
NiV infection and disease [31,32,33,34,35].
Based on these initial findings, a second experiment was carried
out in five AGMs (Subjects 4–8). NiV was inoculated i.t. and doses
ranged from 2.56103 to 6.56104 pfu (Table 1). Together, these
data indicated that NiV lethality in AGMs occurred within 9 to 12
days after virus infection with an i.t. or i.t and oral exposure with
doses ranging from ,2.56103 pfu to ,1.36106 pfu of NiV
(Table 1). All animals in these susceptibility studies (Subjects 1–8)
developed a severe acute-respiratory-distress-syndrome (ARDS)-
like disease, associated with copious amounts of sanguinous fluid
and froth (Figure 1A). Gross pathological examination revealed
severely inflated and enlarged lungs with multifocal areas of
congestion and hemorrhage (Figure 1B). Immunohistochemical
and histopathological examination showed significant amounts of
polymerized fibrin and NiV antigen (Figure 1C and 1D).
Endothelial syncytial cells were particularly prominent in tissues
of most animals and vasculitis and its sequelae were the most
common lesions observed. NiV antigen was present in endothelial
and arterial smooth muscle cells in most tissues examined with
lung appearing to be the most severely affected organ (Figure 1E).
Syncytial cells were also prominent in a variety of other tissues
including spleen, a hallmark feature of these paramyxoviruses and
also seen in naturally and experimentally infected animals
(Figure 2) [24,36,37]. NiV is also known for its appearance and
shedding in the urine of infected animals including bats, and the
bladders of infected monkeys were involved showing inflammation
and hemorrhage and high levels of NiV antigen (Figure 3).
Immunohistochemical and histopathological analysis revealed the
presence of NiV antigen, predominantly in endothelial cells and
smooth muscle cells, along with associated pathology in a wide of
variety tissues, including the tongue, salivary gland, larynx and
trachea, heart, gall bladder, kidneys, sex organs, pituitary and
adrenal glands, stomach, small and large intestine, and skeletal
muscles (data not shown).
In addition and of significant importance, most animals showed
evidence of neurologic disease (Table 1 and Figure 4). Severe
congestion with evidence of meningeal hemorrhaging and edema
was observed (Figure 4A). NiV antigen was detected in
endothelial cells in brain of all animals in this study (Subjects 1,
3–8), example shown in Figure 4B and 4C. In addition, most
animals also showed NiV infection of neurons (Figure 4D–F),
often widespread in the brainstem. Further, because of the
observed unique respiratory involvement of the acute NiV
infection in the monkeys, we sought approval for bringing in a
portable X-ray device into the BSL-4 and subsequently carried out
a series of X-ray images on one animal with signs of acute NiV
disease (Subject 3; see Table 1). Here, changes in radiographs
were evident by day 7 when ventrodorsal view showed developing
pneumonia or congestion. At day 10 and 11 congestion and
pneumonia with infiltrates on the lung fields were evident. At day
11 the heart appeared larger and rounder suggestive of pericardial
effusion (Figure 5).
A single animal exposed to a low dose of ,76103 pfu of NiV
(Subject 2) became severely ill on day 4 and remained clinically
severely ill until day 18 at which time the animal began to recover.
Together, these data indicated that NiV lethality in AGMs
occurred within 9 to 12 days after virus infection with an i.t. or i.t
and oral exposure with doses ranging from ,2.56103 pfu to
,1.36106 pfu of NiV (Table 1).
Nipah Viral Loads and Tissue Tropism in African Green
Monkeys
To examine the extent of virus replication and tissue tropism
among monkeys challenged with NiV, the relative quantity of the
NiV RNA was measured in blood as well as swabs obtained from
pharyngeal, rectal, and vaginal (where appropriate) surfaces
sampled the course of infection. In addition, multiple tissues were
harvested from NiV-challenged monkeys at the time of necropsy
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and the relative quantity of NiV RNA was measured. The relative
quantity of NiV RNA was determined utilizing a Taqman probe
that targets the NiV nucleoprotein (N) gene and detects cDNA
derived from both genomic and positive sense RNA [23]. Figure 6
shows a comparison of the NiV RNA levels detected at various
times post infection from a series of whole blood samples and
blood components collected during the initial AGM NiV challenge
study. NiV RNA detection corresponded closely with the onset of
clinical illness and the progression of the disease. Viral RNA was
detected in the plasma of all challenged animals and is the first
clear demonstration of plasma-associated viremia in NiV exper-
imentally infected animals (Figure 6). Virus was also isolated from
some plasma and whole blood samples when available (Table 2).
Whole blood, plasma, and PBMC were also sampled periodically
over a 12 day period following NiV challenge in the 2.56103 to
6.56104 pfu i.t. group (Subjects 4–8). Here, only Subject 7 had
detectible viral RNA at day 7 similar to the low and variable
detection of RNA observed in Subjects 1 and 3 (Figure 6), all
other samples from Subjects 4, 5, 6, and 8 were negative (data not
shown). Together, these data suggest the virus can spread in the
host via a hematagenous route in the cell-free blood compartment.
In almost all cases where NiV N RNA was detected, the highest
RNA levels corresponded with the day of euthanasia or death of
the animal. Subject 2 had an initial peak of viremia on day 10
during a period of severe clinical illness (Table 1), but by day 17
started to recover from disease. Interestingly, although viremia was
detected again on day 21, this animal made a full recovery and was
completely protected from a second NiV challenge 38 days later
(data not shown). For the remaining animals, the correlation of
peak viral RNA in the blood and severe illness suggests a
progressive infection that seeded multiple organs simultaneously
from the initial site of virus replication.
Over the course of the initial study, swab samples from the nasal
passages, pharyngeal surface, rectum, and vaginal mucosa (where
appropriate) were also collected and assayed. No viral RNA was
detected in vaginal samples or from swab samples obtained from
Subject 2 (low challenge dose). Figure 7 shows a comparison of
the relative quantity of NiV RNA detected among the remaining
swab samples. Viral RNA was most often detected in nasal and
throat swabs. Longitudinal periodic detection (Subject 3:
Figure 7A) was similar to observations made in the cat model.
The detection of viral RNA in Subject 1 swab samples (Figure 7B)
was co-incident with an increased burden of virus in blood and
tissue samples and severe acute disease. Together, these results
indicate virus can be detected at multiple mucosal surfaces of the
respiratory system.
The gross pathology and immunohistochemistry staining of
tissues from the infected AGM subjects suggest spread of the virus
occured rapidly (3–4 days post-infection) to numerous organ
systems. Detection of viral RNA among a variety of tissue samples
Table 1. Clinical description and outcome of Nipah virus challenged monkeys.
Subject No. Sex Dose (pfu) Route Clinical illness Clinical and gross pathology
1 Male 1.36106 i.t., oral Depression, lethargy, fever, loss of appetite,
severe dyspnea, open-mouth breathing.
Animal euthanized on day 9.
Thrombocytopenia; excess blood-tinged pleural fluid;
severely inflated, enlarged lungs with multifocal areas of
congestion and hemorrhage; copious sanguinous frothy
fluid exuding from nose and mouth; hemorrhages on
mucosal surface of urinary bladder.
2 Male 7.06103 i.t., oral Depression, lethargy, loss of appetite from day
4–17, dyspnea, open-mouth breathing, nausea,
lymphadenopathy, ecchymotic rash at
venipuncture site, muscle twitches, behavioral
changes. Recovered after long convalescence.
Mild thrombocytopenia.
3 Female 8.16104 i.t., oral Depression, lethargy, fever, loss of appetite,
severe dyspnea, open-mouth breathing. X-ray
showed pleural effusions. Nausea at end
stages. Animal succumbed on day 11.
Excess blood-tinged pleural fluid; severely inflated,
enlarged lungs with multifocal areas of congestion and
hemorrhage; petechial to ecchymotic hemorrhages on
mucosal surface of urinary bladder; apparent meningitis.
4 Male 6.56104 i.t. Depression, lethargy, fever, loss of appetite,
open-mouth breathing. X-ray showed pleural
effusions. Animal euthanized on day 10.
Mild thrombocytopenia; rectal bleeding; excess blood-
tinged pleural fluid; severely inflated, enlarged lungs with
multifocal areas of congestion and hemorrhage;
hemorrhages on mucosal surface of urinary bladder.
5 Male 5.96104 i.t. Depression, lethargy, loss of appetite, open-
mouth breathing. X-ray showed pleural
effusions. Animal euthanized on day 11.
Thrombocytopenia; excess blood-tinged pleural fluid;
severely inflated, enlarged lungs with multifocal areas of
congestion and hemorrhage.
6 Male 2.36104 i.t. Depression, lethargy, fever, loss of appetite,
open-mouth breathing, loss of balance. X-ray
showed pleural effusions. Animal succumbed
on day 9.
Thrombocytopenia; excess blood-tinged pleural fluid;
severely inflated, enlarged lungs with multifocal areas of
congestion and hemorrhage; hemorrhages on mucosal
surface of urinary bladder.
7 Male 7.06103 i.t. Depression, lethargy, loss of appetite, open-
mouth breathing. X-ray showed pleural
effusions. Animal euthanized on day 9.
Thrombocytopenia; rectal bleeding; excess blood-tinged
pleural fluid; severely inflated, enlarged lungs with
multifocal areas of congestion and hemorrhage;
hemorrhages on mucosal surface of urinary bladder.
8 Male 2.56103 i.t. Depression, lethargy, loss of appetite, open-
mouth breathing. X-ray showed pleural
effusions. Animal succumbed on day 12.
Thrombocytopenia; excess blood-tinged pleural fluid;
severely inflated, enlarged lungs with multifocal areas of
congestion and hemorrhage; sanguinous frothy fluid
exuding from nose and mouth; hemorrhages on mucosal
surface of urinary bladder; apparent meningitis.
i.t., intratracheal; pfu, plaque forming unit.
doi:10.1371/journal.pone.0010690.t001
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Figure 1. NiV pathogenesis in the African green monkey. Panels A, B, D, and E; Subject 1 euthanized on day 9 after i.t. and oral challenge with
1.36106 pfu of NiV. Panel C; Subject 3 that succumbed on day 11 after i.t. and oral challenge to 8.16104 pfu of NiV. (A) Sanguinuous fluid/froth
exuding from nares and mouth. (B) Severely enlarged lungs; multifocal areas of congestion and hemorrhage. (C) Lung, right diaphragmatic lobe by
immunohistochemical stain showing abundance of polymerized fibrin in and around alveolar spaces (arrows); 406magnification. (D) Lung, right
diaphragmatic lobe by PTAH stain showing abundance of polymerized fibrin in and around alveolar spaces (arrows); 1006 magnification. (E)
Localization of NiV antigen by immunohistochemical stain within a lung blood vessel with endothelial syncytia (arrow) and scattered foci of
immunopositive cells (brown) abundant in alveolar septae; 4006magnification.
doi:10.1371/journal.pone.0010690.g001
Nipah Nonhuman Primate Model
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following necropsy (Subjects 1, 3–8) demonstrated the virus can be
found in virtually every organ system sampled at the time of death
depending on the animal examined (Figure 8). Viral RNA was
highest among the spleen, adrenal gland, axillary lymph node, and
pancreas. Other tissues with high levels of viral RNA included the
brain, spleen and kidney. Further study is required to establish the
time course of infection of these organ systems. Viral RNA was
detected in only a single lung sample even though viral antigen can
clearly be demonstrated in all of the lungs from challenged
animals. The extensive lung pathology, severe necrosis and fibrin
deposition, observed at the time of necropsy, likely contributed to
the inability to detect viral RNA or isolate 18S rRNA from these
sites.
Discussion
In the present study, we investigated a new nonhuman primate
model of acute NiV infection and pathogenesis using AGMs.
These are the first experiments conducted in any large nonhuman
primate species using a henipavirus (NiV). Unlike the previously
reported NiV cat, hamster and squirrel monkey models, severe
respiratory pathology, neurological disease and generalized
vasculitis all manifested in NiV-infected monkeys, providing an
accurate reflection of what is observed in NiV-infected humans.
Here, we have observed a uniformly lethal disease with doses as
low as ,26104 pfu. A wider experiment now needs to be
conducted to accurately define the minimal lethal infectious dose
of NiV in this new model. Gross pathological findings revealed
widespread tissue distribution of NiV with findings quite similar to
those reported in NiV-infected humans, characterized as a
systemic vascular disease with extensive inflammation in the
respiratory epithelium associated with viral antigen and endothe-
lial syncytia, and the brain also affected with vascular lesions.
A number of NiV RNA positive swabs from rectal, throat and
nasal-oral samples were identified suggesting the possibility of
virus-shedding. In addition, heavy involvement of virus infection
and replication was seen in the bladder, and henipaviruses have
been shown to be shed in urine. Viral shedding at the mucosal
surfaces may facilitate the transmission of the virus among
mammalian species in the absence of the reservoir host, including
among humans. Person-to-person transmission documented
during repeated epidemics in Bangladesh can potentially be
explained as resulting from the aerosolization of viral particles
shed at the surface of the pharynx. Future experimentation
focusing on the amounts and location of infectious virus shedding
will be important.
We isolated virus from subjects 1 through 5 from plasma or
whole blood samples. These data indicate a low-level viremia can
be detected prior to the advancement of the disease in the animal.
Detection of the virus principally among plasma samples of the
animals supports the PCR data in showing the virus likely
disseminates to multiple organ systems from the initial site of
infection by hematogenous spread in the cell-free blood compo-
nent. Virus isolation from blood and plasma samples was
consistently difficult when compared to the robust results detected
by PCR. This phenomenon is not, however, unexpected as RT-
Figure 2. NiV infection and pathogenesis in the spleen. Panels A–D; Subject 1 that succumbed on day 9 after i.t. and oral challenge with
1.36106 pfu of NiV. (A) Localization of NiV by immunohistochemistry; 206magnification. Scattered foci of immunopositive cells (brown) abundant in
the parafollicular area. Note severe lymphocytolysis of follicle. (B) Localization of fibrin by immunohistochemistry showing abundance of fibrin
(brown) in and around follicle from different section than panel A; 206magnification. A multinucleate giant cell is evident in parafollicular area
(arrow). (C) Transmission electron micrograph of spleen multinucleate giant cell 4,0006magnification, Nu, nucleus and asterisk indicates prominent
intracytoplasmic paramyxoviral inclusions; and D: 20,0006magnification of asterisk indicated area shown in panel C.
doi:10.1371/journal.pone.0010690.g002
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PCR is far more sensitive than virus plaque assay. Further,
detection of virus in RT-PCR is not limited to infectious particles,
but also measures non-infectious particles and free viral RNA
among samples. As anticipated from those observations, we also
measured a wide presence of NiV RNA across a variety of tissue
samples. Indeed, one of the most encouraging signs from the
studies reported here was the presence of NiV RNA in neuronal
tissue in conjunction with immunohistochemical staining of viral
antigen in endothelial cells in the brain.
This is the first report demonstrating an acute, highly
pathogenic and lethal NiV infection model in a nonhuman
primate, the AGM, and provides a path for the establishment of a
BSL-4-restricted primate animal model for NiV. There are
currently no approved antiviral drugs or vaccines available for
the henipaviruses, and neither virus productively infects or causes
disease in typical small animal models, including mice or rabbits
[5,29]. Recently, the susceptibility of squirrel monkeys to NiV was
examined [38]. Although some squirrel monkeys demonstrated
limited similarities to NiV pathogenesis in humans only 50% of
challenged animals exhibited any clinical signs with most
remaining well, even following intranasal or intravenous delivery
of doses as high as 107 pfu of NiV. Among other smaller animal
models explored, the response to either NiV or HeV in guinea pigs
has been reported to be highly variable. Although a generalized
vascular disease was observed with HeV in guinea pigs there was
little or no pulmonary edema [39,40]. Infection of guinea pigs with
high doses of NiV (107 PFU) showed only transient clinical signs
followed by recovery [41] and another study using a high dose of
virus by intraperitoneal administration produced disease in less
than half of challenged animals [42]. There have also been some
potential limitations noted in two other well-characterized animal
models, the cat and hamster [24,39,41,43,44], particularly no
overt CNS pathogenesis or respiratory disease, respectively. Only
the recently described ferret model of NiV infection exhibited both
severe respiratory and neurological disease and generalized
vasculitis in which the underlying pathology closely resembled
NiV-mediated disease seen in humans [28].
In summary, our findings reported here provide evidence of a
new, consistent and highly pathogenic, NHP model of NiV
infection that will be critical for future work on this important
Figure 3. NiV infection and pathogenesis in the urinary bladder. Subject 3 that succumbed on day 11 after i.t. and oral exposure to
8.16104 pfu of NiV. (A) Petechial to ecchymotic hemorrhages on mucosal surface of urinary bladder of animal of animal at necropsy. (B) Bladder ulcer
showing inflammation and hemorrhage by H&E staining; 4006magnification. (C) Bladder ulcer by immunohistochemistry staining of NiV antigen;
4006magnification.
doi:10.1371/journal.pone.0010690.g003
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Figure 4. NiV infection and pathogenesis in the brain. Subject 3 that succumbed on day 11 after i.t. and oral exposure to 8.16104 pfu of NiV.
(A) Brain, severe congestion (black arrows) with possible meningeal hemorrhage; fluid (white arrows) suggests mild to moderate meningeal edema;
(B) brain, cerebrum, double labeling for an endothelial cell marker (von Willebrand’s factor) (green) and NiV antigen (red) showing co-localization of
NiV with the endothelium. Immuofluorescence method with DAPI counterstain; 4006magnification. Subject 6 that succumbed on day 10 after i.t.
challenge with 2.36104 pfu of NiV; (C) brain, cerebrum (corpus striatum), localization of NiV antigen by immunohistochemistry, immunopositive cells
(brown) associated with the endothelium; 4006magnification. Subject 8 that succumbed on day 12 after i.t. challenge with 2.56103 pfu of NiV; (D)
brain, cerebrum (frontal cortex), localization of NiV antigen by immunohistochemistry, strong cytoplasmic and nuclear immunopositive neurons and
processes. (E) Subject 6 brain stem and neurons with intranuclear inclusion bodies (white arrow) and intracytoplasmic inclusion bodies (black arrow),
H&E staining; 4006 magnification. Subject 5 that succumbed on day 11 after i.t. exposure to 5.96104 pfu of NiV; (E) brain stem
immunohistochemistry staining of NiV antigen in same area as in (D) with antigen detected in neuron cell body and axon as well as surrounding
cells; 4006magnification.
doi:10.1371/journal.pone.0010690.g004
Figure 5. Progressive NiV pathogenesis in the African green monkey analyzed by X-ray autoradiography. Subject 3 that succumbed on
day 11 after i.t. and oral exposure to 8.16104 pfu of NiV. X-ray images of chest, days 3 to 11 showing progressive lung pathology. Day 7, evidence of
developing pneumonia or congestion. At day 10 and 11 congestion and pneumonia with infiltrates on the lung fields. These are the first X-ray images
of severe lung pathology induced by a BSL-4 restricted viral pathogen.
doi:10.1371/journal.pone.0010690.g005
Nipah Nonhuman Primate Model
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emerging pathogen. Based on all available reports to date, our
NHP model of acute NiV infection appears to provide one of the
best reproductions of human pathology observed. Together, the
AGM and ferret models of NiV infection appear to be the best
available platforms to comply with the ‘‘two animal rule’’ and will
be critical in the evaluation of both passive and active
immunization or therapeutic strategies for human use [45,46].
Materials and Methods
Ethics Statement
Animal studies were performed in BSL-4 biocontainment at
USAMRIID and were approved by the USAMRIID Laboratory
Animal Use Committee. Animal research was conducted in
compliance with the Animal Welfare Act and other Federal
statutes and regulations relating to animals and experiments
Figure 6. The normalized relative quantity of NiV RNA detected
among blood samples from NiV-infected AGMs. Taqman RT-PCR
was used to determine the relative NiV RNA level among samples of
whole blood or blood components separated by Ficoll density
centrifugation as described in the methods. (A) Low challenge dose,
Subject 2; (B) Medium challenge dose, Subject 3; and (C) high challenge
dose Subject 1.
doi:10.1371/journal.pone.0010690.g006
Table 2. Viral load in African green monkeys after Nipah virus
challenge.
Subject
No.
Day of
death Sample Days after challenge
3 4 7 8 9 10 11 14
1 9 Plasma 0 0 2.65 NT 4.16
2 Survived Plasma 0 0 0 NT NT 0 NT 0
Whole blood 0 0 1.40 NT NT 0 NT 0
3 11 Plasma 0 0 0 NT 0 1.40 0
Whole blood 0 0 0 NT NT
4 10 Plasma 0 0 0 NT NT 0
Whole blood 0 0 0 NT NT 0
5 11 Plasma 0 0 0 NT NT 0 0
Whole blood 0 0 0 NT NT 0 0
6 9 Plasma 0 0 0 NT
Whole blood 0 0 0 NT
7 9 Plasma 0 0 0 NT 0
Whole blood 0 0 0 NT 0
8 12 Plasma 0 0 0 NT NT 0 NT
Whole blood 0 1.40 0 NT NT 0 NT
*Log 10 pfu of Nipah virus per ml of plasma; NT: not tested.
doi:10.1371/journal.pone.0010690.t002
Figure 7. The relative quantity of NiV RNA detected by Taqman
RT-PCR. Shown are the results from nasal, pharyngeal, rectal, and
vaginal swabs from challenged AGM specimens at a series of time
points during infection. (A) Medium challenge dose, Subject 3; (B) High
challenge dose, Subject 1.
doi:10.1371/journal.pone.0010690.g007
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involving animals and adheres to the principles stated in the Guide
for the Care and Use of Laboratory Animals, National Research Council,
1996 [47]. The facility where this research was conducted is fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International.
Virus
NiV was obtained from a patient from the 1998–99 outbreak in
Malaysia [48]. NiV stocks were prepared by three passages on
Vero cells (stock virus titer 16107 pfu/ml).
Animal Studies
An environmental enrichment strategy for animals was
unrestricted and provided by toys, treats, fresh fruits and
vegetables. Animals were monitored daily for health, humane
treatment and husbandry conditions, and acclimated to a BSL-4
animal room for a minimum of 5 days before protocol
commencement. All procedures were carried out with sedated
animals and all NiV-infected animals were closely monitored for
signs of clinical illness and a general distress and a humane
endpoint scoring system was used to determine study endpoint.
Eight henipavirus-seronegative adult African green monkeys
(AGM) (Chlorocebus aethiops) (5–7 kg) were used for these studies.
Animals were exposed to NiV by intratracheal (i.t.) or i.t. and oral
routes with a range of virus doses as shown in Table 1. All
animals were closely monitored for evidence of clinical illness
(temperature, respiration, anorexia, dehydration, central nervous
system disturbances, reduced activity and changes in behavior,
and changes in complete blood count and chemistry) following
NiV challenge. Physical exams and blood and swabs (nasal, oral,
rectal) were collected before NiV challenge and at 3, 4, 7, 10, and
14, days after NiV challenge.
Hematology and Serum Biochemistry
Total white blood cell counts, white blood cell differentials, red
blood cell counts, platelet counts, hematocrit values, total
hemoglobin, mean cell volume, mean corpuscular volume, and
mean corpuscular hemoglobin concentration were determined
from blood samples collected in vacutainer tubes containing
EDTA, by using a laser-based hematologic Analyzer (Coulter
Electronics, Hialeah, FL, USA). Serum samples were tested for
concentrations of albumin (ALB), amylase (AMY), alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alka-
line phosphatase (ALP), gamma-glutamyltransferase (GGT),
glucose (GLU), cholesterol (CHOL), total protein (TP), total
bilirubin (TBIL), blood urea nitrogen (BUN), and creatinine
(CRE) by using a Piccolo Point-Of-Care Blood Analyzer (Abaxis,
Sunnyvale, CA, USA).
Sample Collection and RNA Isolation
Swab (oral, nasal, rectal, and vaginal) and blood samples were
collected as described above. Tissue samples (liver, spleen, kidney,
adrenal, lung, lymph node, pancreas, brain, and bone marrow)
were harvested from animals at the time of necropsy. Blood
samples were collected in vacutainer tubes containing EDTA and
a portion of each was separated into individual blood components
(plasma, granulocytes, peripheral blood mononuclear cells, and
lysed red blood cells) by gradient centrifugation using Ficoll 400
(Sigma-Aldrich, St. Louis, MO) at 4006g for 45 min at room
temperature. Tissue samples were ground in TriPure reagent
(Roche Applied Sciences, Indianapolis, IN) at a concentration of
10% w/v. Blood samples were immediately diluted in TriPure
Isolation Reagent at a ratio of 1 part plasma or swab sample to 4
parts TriPure reagent, 1 part whole blood, granulocytes, lysed red
blood cells, or PBMC sample to 8 parts TriPure reagent. TriPure
diluted samples were stored at 280uC. All samples were thawed at
room temperature prior to RNA isolation. Total RNA was isolated
from each TriPure dilute sample and each sample was
resuspended with 35 ml of ultrapure water treated with 0.1%
diethylpyrocarbonate (DEPC; Invitrogen, Carlsbad, CA). Samples
of purified RNA were stored at 220uC.
TaqMan PCR
TaqMan PCR was performed using the primer sets and probes
as previously described [23]. Samples were amplified with a
GeneAmp 7500 Sequence Detection System (Applied Biosystems).
Ct values representing NiV RNA in samples were analyzed and
data recorded as relative quantity or relative quantity per ml of
sample.
Virus Isolation
Virus isolation was only attempted from specimens positive for
NiV RNA by PCR. Virus titration was performed by plaque assay
on Vero cells as previously described [49]. Briefly, increasing 10-
fold dilutions of the samples were adsorbed to Vero monolayers in
duplicate wells (0.2 ml per well); thus, the limit for detection was
25 pfu/ml.
Histopathology and Immunohistochemistry
A complete necropsy was performed on all animals. Tissue
samples of all major organs were collected from each monkey for
histopathologic and immunohistochemical examination and were
immersion-fixed in 10% neutral buffered formalin. Replicate
sections of spleen, liver, lung, kidney, axillary lymph nodes, and
inguinal lymph nodes were stained with phosphotungstic hema-
toxylin (PTAH) to demonstrate polymerized fibrin [50]. All
immunohistochemical staining was done using an immunoperox-
idase-based system (Envision+, DAKO Corporation, Carpenteria,
CA). Tissue sections were pretreated with a TRIS/EDTA buffer
at 97uC for 30 min and blocked with 5% normal goat serum. The
primary antibody was either a rabbit anti-NiV polyclonal antibody
[37] diluted 1:1000, incubated for 30 min at room temperature or
a monoclonal antibody to fibrin II (NYB-T2G1, Accurate
Chemical Scientific Corporation, Westbury, NY) diluted 1:100,
incubated overnight. Sections were rinsed, and then exposed to a
peroxidase -labeled polymer (EnvisionH, DAKO) for 30 min.
Color development was attained by exposing tissue to 3,39-
diaminobenzidine (DAB) for 5 min and counter-stained in
hematoxylin.
Electron Microscopy
Select tissues for ultrastructural examination were immersion-
fixed in 4% formaldehyde plus 1% glutaraldehyde in 0.1 mol/L
Millonig’s phosphate buffer for transmission electron microscopy.
Figure 8. The relative quantity of NiV RNA detected by Taqman RT-PCR among AGM tissue samples obtained at necropsy from all
Subjects except Subject 2 (survived). Tissue samples were stored in TriPure reagent and total RNA from each sample was isolated according to
the manufacturer’s directions following homogenization. (A) Subject 1; (B) Subject 3; (C) Subject 4; (D) Subject 5; (E) Subject 6; (F) Subject 7; (G)
Subject 8. Abbreviations: axillary lymph node (Ax. LN), inguinal lymph node (ing. LN), mesenteric lymph node (Mes. LN), and mandibular lymph node
(mand. LN).
doi:10.1371/journal.pone.0010690.g008
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Tissues were postfixed in 1% osmium tetroxide in 0.1 mol/L
phosphate buffer, rinsed, stained with 0.5% uranyl acetate in
ethanol, dehydrated in graded ethanol and propylene oxide, and
embedded in Poly/Bed 812 resin (Polysciences, Warrington, PA).
Ultrathin sections were cut, placed on 300-mesh nickel TEM
grids, stained with uranyl acetate and lead citrate, and examined
using a JEOL 1010 transmission electron microscope (JEOL Ltd.,
Peabody, MA) at 80 kV.
X-Ray images
X-ray images were obtained using the The MinXray model HF
100/30 portable x-ray unit (Northbrook, IL) operated at 50 kV
12 mAs at 0.40 seconds at a distance of 36 inches from the subject.
Fuji Type C digital 14617 inch cassettes were employed and
processed using the Fuji Smart CRH processor (Fujifilm USA,
Stamford, CT).
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